05-05-06

PTO/SB/21 (09-04) Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

E Wo,		Application Number		10/656,895
TRANSMITTAL FORM		Filing Date		September 5, 2003
		First Named Inventor		Scott A. Waldman
The state of the s		Art Unit		1643
7 & TRACEMENT (to be used for all correspondence after	initial filino)	Examiner Name		Rawlings, Stephen L.
Total Number of Pages in This Submiss		Attorney Docket Numb	er	TJU0007-103
	ENCLO	SURES (check all that ap	ply)	
Fee Transmittal Form	☐ Drawing(s	5)		After Allowance Communication to TC
Fee Attached	Licensing-related Papers			Appeal Communication to Board of Appeals and Interferences
Amendment / Reply	Petition		Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)	
After Final	- Comment	o Convert to a al Application	□ F	Proprietary Information
Affidavits/declaration(s)		Attorney, Revocation of Correspondence		Status Letter
Extension of Time Request	Terminal Disclaimer			Other Enclosure(s) please identify below):
Express Abandonment Request	Request for Refund CD, Number of CD(s)			n SB08a (1p.); (2) References Cited, (2) rences Enclosed.
Supplemental Information Disclosure Statement	☐ Landscape Table on CD			
Certified Copy of Priority Document(s)	Remarks EXPRESS MAIL LABEL NO: EV770975215US			
Reply to Missing Parts/	DATE OF DEPOSIT: 5/3/2006			
Incomplete Application Reply to Missing Parts under 37 CFR1 52 or 1 53	EV770975215US			

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT Firm Cozen O'Connor Signature Printed Name Mark DeLuca Reg. Date 2006 33,229 No.

under 37 CFR1.52 or 1.53

CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450,

dexamina, VA 22313-1430 on the date shown below.				
Signature			····	
Typed or printed name		Date		

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

MAY 0 9 200 In Re

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Scott A. Waldman et al.

Erial No.: 10/656,895

Group Art Unit: 1643

Filing Date: September 5, 2003

Examiner: Rawlings, Stephen L.

For: Compositions that specifically bind to colorectal cancer cells and methods of using

the same

Express Mail Label No. EV770975215US Date of Deposit: 5/3/2006

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 C.F.R. §§ 1.56 and in accordance with 37 C.F.R. §§ 1.97 and 1.98, information relating to the above-identified application is hereby disclosed, the Examiner in charge of the above-identified application is requested to consider and make of record the references listed on the PTO Form SB/08B, formerly known as PTO Form 1449, submitted herewith.

Inclusion of the information submitted herewith is not to be construed as an admission that the information is material as that term is defined in 37 C.F.R. § 1.56(b).

In accordance with 37 C.F.R. § 1.97(g), the filing of this Supplemental Information Disclosure Statement shall not be construed to mean that a search has been made.

This Supplemental Information Disclosure Statement is being filed:

	within three months of the filing date of the patent application.
	within three months of the date of entry into the national stage as set forth in 37 C.F.R. § 1.491 of the international application.
\boxtimes	before the mailing date of a first Office Action on the merits.
	before the mailing date of a first Office Action on the merits after the filing of a Request for Continued Examination under § 1.114.

	of a F date	the mailing date of a first Office Action on the merits or after the filing Request for Continued Examination under § 1.114, but before the mailing of a Final Office Action under 37 C.F.R. § 1.116 or a Notice of vance under 37 C.F.R. § 1.311, and accordingly is accompanied by:	
		the Statement under 37 C.F.R. § 1.97(e) (see "Statement" below);	
		or	
		the Fee of \$180.00 set forth in 37 C.F.R. § 1.17(p); or	
		No fee is owed by the applicant(s).	
	Stater Final C.F.R	coordance with 37 C.F.R. § 1.129(a), this Information Disclosure ment is being filed in connection with the first or second After Submission, and accordingly is accompanied by the Statement under 37 § 1.97(e) (see "Statement" below) and the fee of \$180.00 as set forth in F.R. § 1.17(p), is attached.	
	after the mailing date of a Final Office Action under 37 C.F.R. § 1.116 or a Notice of Allowance under 37 C.F.R. § 1.311, but before, or simultaneously with, the payment of the Issue Fee, and accordingly is accompanied by the Statement under 37 C.F.R. § 1.97(e), and the Fee of \$180.00 set forth in 37 C.F.R. §1.17(p).		
\boxtimes		es of the references listed on the attached PTO Form SB/08B, formerly n as PTO Form 1449, are enclosed.	
EXCE	EPT TI	HAT:	
		In view of the voluminous nature of references, and the likelihood that these reference are available to the Examiner, copies are not enclosed herewith.	
		In accordance with 37 C.F.R. § 1.98(d), copies of the following references listed on the attached PTO Form SB/08A and PTO Form SB/08B, formerly known as PTO Form 1449 are not enclosed herewith because they were previously cited by or submitted to the U.S. Patent and Trademark Office in patent application(s) @@ for which a claim for priority under 35 U.S.C. § 120 have been made in the instant application.	
		If any of the foregoing publications are not available to the Examiner, Applicant will endeavor to supply copies at the Examiner's request.	
Staten	nent ui	nder 37 C.F.R. § 1.97(e)	
	The undersigned attorney hereby states that each item information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign patent application not more than three months prior to the filing of the Information Disclosure Statement.		

State	ment under 37 C.F.R. § 1.704(d)
	The undersigned attorney hereby states that each item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart application and the communication was not received by any individual designated in §1.56(c) more than 30 days prior to the filing of the Information Disclosure Statement.
Fees	
\boxtimes	No Fee is owed by the applicant(s).
	The Supplemental Information Disclosure Statement Fee of \$180.00 under 37 C.F.R. § 1.17(p) is enclosed herewith.
	The Petition Fee of \$130.00 under 37 C.F.R. § 1.17(i)(1) is enclosed herewith.
Meth	od of Payment of Fees
	Attached is a check in the amount of \$ This form is submitted in duplicate.
	Charge Deposit Account No. 50-1275 in the amount of \$180.00. This form is submitted in duplicate.
\boxtimes	Please charge any deficiency or credit any overpayment to Deposit Account 50-1275.
\boxtimes	No fee or Statement is required under 37 C.F.R. § 1.97(b).
	Respectfully submitted,

Dated: May 3, 2006

COZEN O'CONNOR, P.C. 1900 Market Street, 5th Floor Philadelphia, PA 19103-3508 (215) 665-2000 - Telephone (215) 665-2013 - Facsimile Mark DeLuca

Registration No. 33,229

PTO/SB/08b(08-03)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

TJU0007-103

Attorney Docket Number

1-4	are required to respond to a collection	Of Information unless it contains a valid Civib control num	
Substitute Capetal OB/PTO	Complete if Known		
INFORMATION DICCLOSURE	Application Number	10/656,895	
INFORMATION DISCLOSURE	Filing Date	September 5, 2003	
STATEMENT BY APPLICANT	First Named Inventor	Scott A. Waldman	
	Art Unit	1643	
(Use as many sheets as necessary)	Examiner Name	Rawlings, Stephen L.	

Sheet

of

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	1	Pearlman et al., "A splice variant of the transcript for guanylyl cyclase C is expressed in human colon and colorectal cancer cells," <i>Dig. Dis. Sci.</i> (2000) 45(2):298-305.	
	2	Waldman et al., "Heterogeneity of guanylyl cyclase C expressed by human colorectal cancer cell lines in vitro," Cancer Epidemiol. Biomarkers Prev. (1998) 7(6):505-514.	
		·	

Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time your requires to complete the found required to the Chief. case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.